For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220620:nRST4368Pa&default-theme=true
RNS Number : 4368P Verici Dx PLC 20 June 2022
Verici Dx plc
("Verici Dx" or the "Company")
Distribution of Verici Dx shares by EKF Diagnostics Holdings plc
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, notes the announcement made by EKF Diagnostics Holdings PLC
("EKF") this morning (RNS 3845P), declaring the distribution of its Verici Dx
Investment Shares to Relevant EKF Shareholders via a distribution in specie.
These shares comprise of 9,098,611 ordinary shares in Verici Dx of £0.001
each and are subject to a Lock-up Period of 365 days from transfer.
Full details can be seen in the EKF announcement here:
https://www.londonstockexchange.com/news-article/EKF/distribution-of-shares-in-verici-dx-plc/15501862
(https://www.londonstockexchange.com/news-article/EKF/distribution-of-shares-in-verici-dx-plc/15501862)
Capitalised terms in this announcement carry the same definitions as in the
EKF announcement.
Enquiries:
Verici Dx www.v (http://www.vericidx.com) ericidx (http://www.vericidx.com) .com
(http://www.vericidx.com)
Sara Barrington, CEO Via Walbrook PR
Julian Baines, Chairman
Singer Capital Markets (Nominated Adviser & Broker) Tel: 020 7496 3000
Aubrey Powell / Kailey Aliyar / Rachel Hayes
Walbrook PR Limited Tel: 020 7933 8780 or vericidx@walbrookpr.com
(mailto:renalytix@walbrookpr.com)
Paul McManus / Sam Allen Mob: 07980 541 893 / 07502 558 258
About Verici Dx plc www.vericidx.com (http://www.vericidx.com)
Verici Dx is a developer of a complementary suite of leading-edge tests
forming a kidney transplant platform for personalised patient and organ
response risk to assist clinicians in medical management for improved patient
outcomes. The underlying technology is based upon artificial intelligence
assisted transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for transplant
prognosis of risk of injury, rejection and graft failure from pre-transplant
to late stage. The Company also has a mission to accelerate the pace of
innovation by research using the fully characterised data from the underlying
technology and collaboration with medical device, biopharmaceutical and data
science partners.
The foundational research was driven by a deep understanding of cell-mediated
immunity and is enabled by access to expertly curated collaborative studies in
highly informative cohorts in kidney transplant.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END MSCBKKBKABKKOAB